INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023

Rhea-AI Summary

INOVIO (NASDAQ: INO) announced that an abstract for INO-3107, targeting Recurrent Respiratory Papillomatosis (RRP), has been accepted for oral presentation at the ABEA program during the COSM 2023 in Boston, scheduled for May 5, 2023. The presentation will showcase safety and immunogenicity data from both cohorts of a recently completed Phase 1/2 trial involving 32 RRP patients. RRP, primarily caused by HPV-6 and HPV-11, leads to the growth of benign warts in the respiratory tract but can cause serious complications. INO-3107 is a clinical-stage DNA medicine aimed at inducing T cell responses against these HPV types, potentially curbing papilloma growth. In July 2020, INO-3107 received Orphan Drug Designation from the FDA.

Positive

• Abstract for INO-3107 accepted for presentation at prestigious COSM 2023.
• Safety and immunogenicity data from the Phase 1/2 trial will be shared, indicating progress in research.
• INO-3107 is designed to elicit targeted immune responses against HPV, addressing a significant medical need.

Negative

• Limited patient cohort of 32 may limit the generalizability of trial results.
• RRP is a rare and debilitating disease, highlighting the limited market for INO-3107 despite its potential efficacy.

Safety and Immunological data from both cohorts of the recently completed Phase 1/2 trial will be presented on May 5^th

PLYMOUTH MEETING, Pa., April 27, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that an abstract has been accepted for oral presentation on INO-3107 for the treatment of Recurrent Respiratory Papillomatosis (RRP) at this year's American Broncho-Esophagological Association (ABEA) program at the Combined Otolaryngology Spring Meetings (COSM) in Boston, Massachusetts.

"We are pleased that lead investigator Dr. Ted Mau will have the opportunity to share additional encouraging insights on the safety and immunogenicity of INO-3107 from both cohorts of our recently completed study," said Dr. Mike Sumner, INOVIO's Chief Medical Officer.

Details of the ABEA at COSM presentation are as follows:

Title: Phase 1/2 Open-label, Multicenter Trial Of INO-3107 With Electroporation In Adult Patients With HPV-6 And/or HPV-11-associated Recurrent Respiratory Papillomatosis: Interim Analysis
Session: ABEA Scientific Session III: Voice 
Session Date and Time: Friday, May 5, 2023, 9:00 am EDT
Location: 304/306 (Hynes)

The presentation will include new safety, immunological, and demographic data from both cohorts of a Phase 1/2 trial evaluating the safety, tolerability, immunogenicity, and efficacy of INO-3107 in 32 patients with HPV-6 and/or HPV-11-associated RRP.

About RRP

RRP is a debilitating and rare disease caused primarily by HPV-6 and/or HPV-11. RRP is characterized by the development of small, wart-like growths, or papillomas, in the respiratory tract. While papillomas are generally benign, they can cause severe, life-threatening airway obstruction and respiratory complications. RRP can also significantly affect quality of life for patients by affecting the voice box, limiting the ability to speak effectively. Surgery to remove papillomas is the standard of care for RRP; however, the papillomas often grow back because the underlying HPV infection has not been eradicated.

The most widely cited U.S. epidemiology data from 1995 cites 14,000 active cases and about 1.8 per 100,000 new cases in adults each year. More recent pediatric epidemiology data cites a range of 0.5 - 0.7 per 100,000 new cases in children in the US each year.

About INO-3107

INO-3107 is INOVIO's clinical-stage DNA medicine product candidate being developed as a potential treatment for RRP. INO-3107 is designed to elicit a targeted T cell response against HPV-6 and HPV-11, the HPV types responsible for causing RRP among other HPV-related diseases. These targeted T cells are designed to seek out and kill infected cells, with the aim of potentially preventing or slowing the growth of new papillomas. INO-3107 received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in July 2020. For more information about our HPV franchise, please visit https://ir.inovio.com/events-and-presentations/default.aspx

About INOVIO

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases. INOVIO's DNA medicines in development are delivered using its investigational proprietary smart device, CELLECTRA^®, to produce immune responses against targeted pathogens and cancers. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267) 440-4298 thomas.hong@inovio.com 

 

View original content:https://www.prnewswire.com/news-releases/inovio-announces-acceptance-of-abstract-for-oral-presentation-on-ino-3107-for-the-treatment-of-recurrent-respiratory-papillomatosis-at-cosm-2023-301809327.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

What is the significance of INO-3107 for RRP treatment?

INO-3107 is being developed to target HPV-6 and HPV-11, aiming to reduce the recurrence of papillomas associated with RRP.

When will INO present data on INO-3107?

Data on INO-3107 will be presented on May 5, 2023, at the COSM 2023 meeting.

What was the size of the trial for INO-3107?

The trial evaluating INO-3107 involved 32 patients with HPV-associated RRP.

What are the implications of receiving Orphan Drug Designation for INO-3107?

Receiving Orphan Drug Designation from the FDA may provide INO-3107 with market exclusivity and other benefits aimed at incentivizing the development of treatments for rare diseases.

What are the potential risks associated with INO-3107?

The efficacy of INO-3107 will depend on trial outcomes; the small size of the study may limit the confidence in results.